Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of neuraminidase inhibitor to preparation of drug for treating myocarditis

A technology for neuraminidase and myocarditis, applied in the field of medicine, can solve the problems of myocarditis, etc.

Active Publication Date: 2018-06-08
CHINA PHARM UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the use of neuraminidase inhibitors in the treatment of myocarditis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: to the therapeutic effect of viral myocarditis

[0016] 1. Test method

[0017] 1. Animal grouping, modeling and administration

[0018] 5-week-old male BALB / c mice were randomly divided into 3 groups, namely control group, model group, oseltamivir phosphate treatment group (OS group), zanamivir treatment group (ZA group), 20 in each group . The control group was intraperitoneally inoculated with 0.1mL Eagle solution without Coxsackievirus B3 (CVB3), and the model group, OS group and ZA group were intraperitoneally injected with 0.1mL containing 1×10 2 TCID 50 The Eagle solution of CVB3 replicated the viral myocarditis model. From the day of inoculation, the OS group was given 10 mg / kg / d oseltamivir phosphate (p.o.), and the ZA group was given 0.4 mg / kg / d zanamivir (i.v.) for 2 consecutive weeks. The control group and model group were given an equal volume of vehicle.

[0019] CVB3 was passaged in HeLa cells, after freezing and thawing and centrifugi...

Embodiment 2

[0035] Example 2: Therapeutic effect on autoimmune myocarditis

[0036] 1. Test method

[0037] 1. Animal grouping, modeling and administration

[0038] 5-week-old male BALB / c mice were randomly divided into 3 groups, namely control group, model group, oseltamivir phosphate treatment group (OS group), zanamivir treatment group (ZA group), 20 in each group . The model group, OS group and ZA group were subcutaneously injected with porcine myocardial myosin (200 μg / cause, about 20 μL / cause) and the same volume of complete Freund’s adjuvant in the groin on the 1st and 5th day respectively, and the control group was injected with the same volume of vehicle and complete Freund's adjuvant. From the day of inoculation, the OS group was given 10 mg / kg / d oseltamivir phosphate (p.o.), and the ZA group was given 0.4 mg / kg / d zanamivir (i.v.) for 3 consecutive weeks; the control group and the model group were given solvent.

[0039] 2. Index detection

[0040] 2 hours after the last a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a neuraminidase inhibitor to preparation of a drug for treating myocarditis. The invention discovers that oseltamivir phosphate or zanamivir as the neuraminidaseinhibitor has an effective treatment effect on a myocarditis model mouse. After the myocarditis model mouse is treated by the oseltamivir phosphate or the zanamivir, the serum cTnI concentration is significantly reduced, so that the degree of myocardial injury is improved; and myocardial case scores are significantly reduced, so that the degree of cardiomyopathy is relieved. Therefore, the oseltamivir phosphate or the zanamivir as the neuraminidase inhibitor can be used for preparing the drug for treating the myocarditis.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the use of neuraminidase inhibitors for preparing medicines for treating myocarditis. Background technique [0002] Neuraminic acid is a class of natural sugar and acid compounds widely present in organisms. It is now confirmed that there are more than 50 natural derivatives of neuraminic acid, and N-acetylneuraminic acid and N-glycolylneuraminic acid are the more common ones. Neuraminic acid is usually linked to the end of glycoconjugates such as glycoproteins and glycolipids in the form of short chain residues. Neuraminic acid is an important biological information transfer molecule, and the neuraminidative modification of cell surface glycoproteins and glycolipids plays a vital role in many biological processes, including cell adhesion, antigen recognition and signal transduction. [0003] In organisms, neuraminidase is an enzyme related to neuraminic acid, which plays an indispensable...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/215A61K31/351A61P9/00
CPCA61K31/215A61K31/351A61K31/7012
Inventor 齐炼文张蕾尹小建李菁马高翔
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com